**Question:** In chronic obstructive pulmonary disease all are seen EXCEPT -

A. Acute exacerbations
B. Bronchiectasis
C. Bronchodilation
D. Pulmonary fibrosis

**Core Concept:**
Chronic obstructive pulmonary disease (COPD) is a group of obstructive airway diseases characterized by progressive airflow limitation, mainly caused by tobacco smoking. The main features include bronchoconstriction, inflammation, and airway wall remodeling.

**Why the Correct Answer is Right:**
In COPD, the primary pathophysiology involves bronchoconstriction, which is primarily due to the effects of cigarette smoke on smooth muscle contraction, mucus production, and goblet cell hyperplasia. Bronchiectasis, on the other hand, is a condition characterized by abnormal dilation of the bronchi, usually caused by infection or inflammation. Pulmonary fibrosis is a condition characterized by excessive scarring and replacement of lung tissue with fibrous connective tissue, leading to impaired lung function.

**Why Each Wrong Option is Incorrect:**
A. Acute exacerbations are temporary worsening of COPD symptoms that can be triggered by infections, allergens, or other factors. While acute exacerbations can occur in COPD, they are not seen as a constant feature of the disease.

B. Bronchiectasis is not a characteristic feature of COPD but rather a separate condition caused by infection or inflammation.

C. Bronchodilation refers to the relaxation of bronchial smooth muscle, which is a primary therapeutic goal in COPD management. However, it is not a feature of the disease itself.

D. Pulmonary fibrosis is a separate condition characterized by excessive scarring and replacement of lung tissue with fibrous connective tissue, leading to impaired lung function. This is not a constant feature of COPD.

**Clinical Pearl:**
A key clinical pearl to remember is that COPD exacerbations, bronchiectasis, and pulmonary fibrosis are separate entities from COPD itself. The primary feature of COPD is bronchoconstriction, airway inflammation, and airway remodeling, which is targeted by bronchodilators like beta-agonists and anticholinergics in COPD management.